Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Ian Michael Estepan, CFO of Sarepta Therapeutics, sold 1,389 shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 4, 2024, Ian Michael Estepan, the Chief Financial Officer of Sarepta Therapeutics, sold 1,389 shares of the company's common stock.
- The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 3, 2021.
- The price per share was $125.32.
- Following the transaction, Estepan directly owns 37,725 shares of Sarepta Therapeutics.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, and it doesn't necessarily reflect a positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is a common occurrence where executives sell shares to cover tax obligations related to equity compensation.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/03/2021 | Date of grant for the restricted stock units that triggered the tax obligation. |
| 03/04/2024 | Date of the stock sale transaction. |
| 03/06/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.